Fudan University Shanghai Cancer Center
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Driven by 5 papers. Top paper: “Clinicopathological and molecular correlates of clinical benefit from disitamab vedotin (RC48), a HER-2-targeting antibody-drug conjugate, in metastatic urothelial carcinoma: a multi-center, real-world study”.
Kaifeng Jin, Ziyue Xu, Han Zeng, Xiaohe Su, Jingtong Xu +8 more
Yu Zhu, Fengmei Fan, Song Chen, Yuan Hong, Yimin Cui +14 more
Yu Zhu, Junchao Huang, Yanfang Zhou, Jinghui Tong, Ping Zhang +11 more
Yu Zhu, Junchao Huang, Yanfang Zhou, Jinghui Tong, Ping Zhang +11 more
Yunong Xu, Chijian Xiang, Yu Zhu, Tongtong Li, Anton V. Sinitskiy +2 more